MENLO PARK, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), an organization devoted to creating revolutionary molecular diagnostic assessments for infectious ailments on the point-of-care, immediately introduced the appointment of Jeryl “Jeri” Hilleman to its Board of Directors. Ms. Hilleman will function Chair of the Audit Committee.
“We welcome Jeri to our Board and look ahead to benefitting from her public firm management as a chief monetary officer and company director at a number of life science firms,” stated Brian Coe, Chief Executive Officer of Talis. “Jeri’s expertise and steering will probably be instrumental as we proceed to scale our enterprise in preparation for the business launch of Talis One™.”
Ms. Hilleman brings over 20 years of govt management and monetary expertise to Talis. She at present serves as Chairman of the Board of Omada Health and is a Director of Novocure, SI-Bone and Minerva Neurosciences. Prior to her determination to deal with board duties full time in 2020, Ms. Hilleman served as a Chief Financial Officer for greater than 20 years at a number of public firms within the life science trade, together with Intersect ENT, Ocera Therapeutics, Amyris, Symyx Technologies and Cytel.
“Driven by the chance to assist firms outline development methods, I look ahead to working with the Talis Board and management workforce of their efforts to rework diagnostic testing for infectious ailments on the point-of-care,” stated Ms. Hilleman.
Ms. Hilleman graduated from Brown University and earned an MBA from the Wharton School of the University of Pennsylvania. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network on the Aspen Institute.
About the Talis One Platform
The Talis One platform is a compact, sample-to-answer, cloud-enabled, molecular diagnostic resolution that, as soon as licensed for advertising and marketing, could possibly be quickly deployed to distributed diagnostic settings within the United States and world wide to diagnose infectious ailments on the point-of-care. The Talis One assays are primarily based on a extremely optimized nucleic acid isothermal amplification chemistry to obtain take a look at efficiency sooner than conventional polymerase chain response (PCR) assessments. The Talis One platform is designed to be used in non-laboratory settings, similar to physicians’ workplaces, hospital emergency departments, pressing care clinics, ambulatory surgical procedure facilities, elder care/assisted dwelling services, and most cancers therapy and dialysis facilities.
COVID-19 is the primary infectious illness that the Talis One platform is designed to detect. Future infectious illness indications might embrace assays for different respiratory infections, similar to influenza, in addition to sexually transmitted infections (STIs) and different infections impacting girls’s well being. The Talis One platform, at present in improvement, is designed to be managed remotely, to ship take a look at outcomes to a cloud database for safe transmission, storage and evaluate, and to return leads to roughly 25 minutes.
Talis is devoted to remodeling diagnostic testing by creating and commercializing revolutionary merchandise which might be designed to allow correct, low price and fast molecular testing for infectious ailments on the point-of-care, starting with COVID-19. The firm is creating Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis is headquartered in Menlo Park, California. For extra info, please go to talis.bio .
Media & Investors